Iron dysregulation in Huntington's disease

Journal of Neurochemistry

Volumn 130, Issue 3, 2014, Pages 328-350

  Muller, Michelle ^a   Leavitt, Blair R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

huntingtin; Huntington's disease; iron; magnetic resonance imaging; microglia; neurodegeneration

Indexed keywords

FERRITIN; GLUTAMIC ACID; HUNTINGTIN; IRON; MUTANT PROTEIN;

AGE; BIOACCUMULATION; BIOLOGICAL ACTIVITY; BRAIN LEVEL; BRAIN REGION; CHEMICAL ANALYSIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE MARKER; EXCITOTOXICITY; GENE MUTATION; HISTOCHEMISTRY; HUMAN; HUNTINGTON CHOREA; IRON BLOOD LEVEL; IRON CHELATION; IRON DYSREGULATION; IRON METABOLISM; IRON METABOLISM DISORDER; IRON OVERLOAD; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; WILD TYPE;

HUNTINGTIN; HUNTINGTON'S DISEASE; IRON; MAGNETIC RESONANCE IMAGING; MICROGLIA; NEURODEGENERATION;

AGING; ANIMALS; BRAIN CHEMISTRY; BRAIN DISEASES; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; IRON; MICE; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

EID: 84904684637     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12739     Document Type: Review

References (280)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
2. Aarts M. M., and, Tymianski M., (2003) Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors. Biochem. Pharmacol. 66, 877-886.
3. Aisen P., Enns C., and, Wessling-Resnick M., (2001) Chemistry and biology of eukaryotic iron metabolism. Int. J. Biochem. Cell Biol. 33, 940-959.
4. Albin R. L., and, Tagle D. A., (1995) Genetics and molecular biology of Huntington's disease. Trends Neurosci. 18, 11-14.
5. Albin R. L., Young A. B., Penney J. B., Handelin B., Balfour R., Anderson K. D., Markel D. S., Tourtellotte W. W., and, Reiner A., (1990) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 322, 1293-1298.
6. Armitage A. E., Eddowes L. A., Gileadi U., Cole S., Spottiswoode N., Selvakumar T. A., Ho L.-P., Townsend A. R. M., and, Drakesmith H., (2011) Hepcidin regulation by innate immune and infectious stimuli. Blood 118, 4129-4139.
7. Arosio P., Ingrassia R., and, Cavadini P., (2009) Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim. Biophys. Acta 1790, 589-599.
8. Arrasate M., and, Finkbeiner S., (2012) Protein aggregates in Huntington's disease. Exp. Neurol. 238, 1-11.
9. Atwal R. S., Xia J., Pinchev D., Taylor J., Epand R. M., and, Truant R., (2007) Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 16, 2600-2615.
10. Auerbach W., Hurlbert M. S., Hilditch-Maguire P., Wadghiri Y. Z., Wheeler V. C., Cohen S. I., Joyner A. L., MacDonald M. E., and, Turnbull D. H., (2001) The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum. Mol. Genet. 10, 2515-2523.
11. Aziz N. A., van Belzen M. J., and, Roos R. A., (2008) Intergenerational CAG repeat instability is highly heritable in Huntington's disease. J. Med. Genet. 45, 766.
12. Baiamonte B. A., Lee F. A., Brewer S. T., Spano D., and, LaHoste G. J., (2013) Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease. PLoS ONE 8, e53606.
13. Bakshi R., Shaikh Z. A., and, Janardhan V., (2000) MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation. NeuroReport 11, 15-21.
14. Bakshi R., Dmochowski J., Shaikh Z. A., and, Jacobs L., (2001) Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J. Neurol. Sci. 185, 19-26.
15. Bartzokis G., and, Tishler T. A., (2000) MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell. Mol. Biol. (Noisy-le-grand) 46, 821-833.
16. Bartzokis G., Aravagiri M., Oldendorf W. H., Mintz J., and, Marder S. R., (1993) Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn. Reson. Med. 29, 459-464.
17. Bartzokis G., Cummings J., Perlman S., Hance D. B., and, Mintz J., (1999) Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56, 569-574.
18. Bartzokis G., Tishler T. A., Shin I.-S., Lu P. H., and, Cummings J. L., (2004) Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. N. Y. Acad. Sci. 1012, 224-236.
19. Bartzokis G., Lu P. H., Tishler T. A., Fong S. M., Oluwadara B., Finn J. P., Huang D., Bordelon Y., Mintz J., and, Perlman S., (2007) Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res. 32, 1655-1664.
20. Beal M. F., Ferrante R. J., Swartz K. J., and, Kowall N. W., (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11, 1649-1659.
21. Benchoua A., Trioulier Y., Zala D., et al,. (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 17, 1652-1663.
22. Bennett E. J., Shaler T. A., Woodman B., Ryu K. Y., Zaitseva T. S., Becker C. H., Bates G. P., Schulman H., and, Kopito R. R., (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448, 704-708.
23. Bermel R. A., Puli S. R., Rudick R. A., Weinstock-Guttman B., Fisher E., Munschauer F. E., 3rd, and, Bakshi R., (2005) Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch. Neurol. 62, 1371-1376.
24. Bezprozvanny I., (2009) Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15, 89-100.
25. Björkqvist M., Wild E. J., Thiele J., et al,. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 205, 1869-1877.
26. van den Bogaard S. J. A., Dumas E. M., and, Roos R. A. C., (2013) The role of iron imaging in Huntington's disease. Int. Rev. Neurobiol. 110, 241-250.
27. Boll M. C., Alcaraz-Zubeldia M., Montes S., and, Rios C., (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem. Res. 33, 1717-1723.
28. Bonilla E., Estévez J., Suárez H., Morales L. M., Chacin de Bonilla L., Villalobos R., and, Dávila J. O., (1991) Serum ferritin deficiency in Huntington's disease patients. Neurosci. Lett. 129, 22-24.
29. Bossy-Wetzel E., Schwarzenbacher R., and, Lipton S. A., (2004) Molecular pathways to neurodegeneration. Nat. Med. 10 (Suppl), S2-S9.
30. Bowling A. C., and, Beal M. F., (1995) Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56, 1151-1171.
31. Brenman J. E., and, Bredt D. S., (1996) Nitric oxide signaling in the nervous system. Methods Enzymol. 269, 119-129.
32. Brouillet E., Condé F., Beal M. F., and, Hantraye P., (1999) Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468.
33. Browne S. E., Bowling A. C., MacGarvey U., Baik M. J., Berger S. C., Muqit M. M., Bird E. D., and, Beal M. F., (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653.
34. Browne S. E., Ferrante R. J., and, Beal M. F., (1999) Oxidative stress in Huntington's disease. Brain Pathol. 9, 147-163.
35. Bush A. I., (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23, 1031-1038.
36. Calabrese V., Cornelius C., Rizzarelli E., Owen J. B., Dinkova-Kostova A. T., and, Butterfield D. A., (2009) Nitric oxide in cell survival: a janus molecule. Antioxid. Redox Signal. 11, 2717-2739.
37. Canals J. M., Checa N., Marco S., Akerud P., Michels A., Perez-Navarro E., Tolosa E., Arenas E., and, Alberch J., (2001) Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J. Neurosci. 21, 117-124.
38. Caron N. S., Desmond C. R., Xia J., and, Truant R., (2013) Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. Proc. Natl Acad. Sci. USA 110, 14610-14615.
39. Cepeda C., Wu N., Andre V. M., Cummings D. M., and, Levine M. S., (2007) The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 81, 253-271.
40. Cheah J. H., Kim S. F., Hester L. D., Clancy K. W., Patterson S. E., 3rd, Papadopoulos V., and, Snyder S. H., (2006) NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 51, 431-440.
41. Chen C.-M., (2011) Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med. J. 34, 135-152.
42. Chen W., Paradkar P. N., Li L., et al,. (2009) Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc. Natl Acad. Sci. USA 106, 16263-16268.
43. Chen J., Marks E., Lai B., Zhang Z., Duce J. A., Lam L. Q., Volitakis I., Bush A. I., Hersch S., and, Fox J. H., (2013a) Iron Accumulates in Huntington's Disease Neurons: Protection by Deferoxamine. PLoS ONE 8, e77023.
44. Chen Y., Khan R. S., Cwanger A., et al,. (2013b) Dexras1, a small GTPase, is required for glutamate-NMDA neurotoxicity. J. Neurosci. 33, 3582-3587.
45. Cherubini A., Péran P., Caltagirone C., Sabatini U., and, Spalletta G., (2009) Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. NeuroImage 48, 29-36.
46. Chinnery P. F., Crompton D. E., Birchall D., et al,. (2007) Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130, 110-119.
47. Choi B. R., Bang S., Chen Y., Cheah J. H., and, Kim S. F., (2013) PKA modulates iron trafficking in the striatum via small GTPase, Rhes. Neuroscience 253, 214-220.
48. Choo Y. S., Johnson G. V. W., MacDonald M., Detloff P. J., and, Lesort M., (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407-1420.
49. Cicchetti F., Prensa L., Wu Y., and, Parent A., (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res. Rev. 34, 80-101.
50. Cisbani G., and, Cicchetti F., (2012) An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis. 3, e382.
51. Connor J. R., and, Menzies S. L., (1996) Relationship of iron to oligodendrocytes and myelination. Glia 17, 83-93.
52. Coppedè F., Mancuso M., Siciliano G., Migliore L., and, Murri L., (2006) Genes and the environment in neurodegeneration. Biosci. Rep. 26, 341-367.
53. Cowan C. M., Fan M. M. Y., Fan J., Shehadeh J., Zhang L. Y. J., Graham R. K., Hayden M. R., and, Raymond L. A., (2008) Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J. Neurosci. 28, 12725-12735.
54. Crapper McLachlan D. R., Dalton A. J., Kruck T. P., Bell M. Y., Smith W. L., Kalow W., and, Andrews D. F., (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
55. Damiano M., Diguet E., Malgorn C., et al,. (2013) A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Hum. Mol. Genet. 22, 3869-3882.
56. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L., and, Bates G. P., (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
57. Davranche A., Aviolat H., Zeder-Lutz G., Busso D., Altschuh D., Trottier Y., and, Klein F. A. C., (2011) Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. Hum. Mol. Genet. 20, 2795-2806.
58. De Domenico I., Zhang T. Y., Koening C. L., et al,. (2010) Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J. Clin. Investig. 120, 2395-2405.
59. De Rooij K. E., De Koning Gans P. A., Roos R. A., Van Ommen G. J., and, Den Dunnen J. T., (1995) Somatic expansion of the (CAG)n repeat in Huntington disease brains. Hum. Genet. 95, 270-274.
60. Deng Y. P., Albin R. L., Penney J. B., Young A. B., Anderson K. D., and, Reiner A., (2004) Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J. Chem. Neuroanat. 27, 143-164.
61. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., and, Marsden C. D., (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
62. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Lees A. J., Jenner P., and, Marsden C. D., (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
63. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J. P., Carraway R., and, Reeves S. A., (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075-1081.
64. Douaud G., Behrens T. E., Poupon C., et al,. (2009) In vivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage 46, 958-966.
65. Dragatsis I., Efstratiadis A., and, Zeitlin S., (1998) Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 125, 1529-1539.
66. Dragatsis I., Levine M. S., and, Zeitlin S., (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26, 300-306.
67. Drayer B., Burger P., Hurwitz B., Dawson D., and, Cain J., (1987) Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? Am. J. Roentgenol. 149, 357-363.
68. Dumas E. M., Versluis M. J., van den Bogaard S. J. A., et al,. (2012) Elevated brain iron is independent from atrophy in Huntington's Disease. NeuroImage 61, 558-564.
69. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali M., Folstein S., Ross C., Franz M., and, Abbott M., (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4, 387-392.
70. Duyao M. P., Auerbach A. B., Ryan A., Persichetti F., Barnes G. T., McNeil S. M., Ge P., Vonsattel J. P., Gusella J. F., and, Joyner A. L., (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269, 407-410.
71. Ehrnhoefer D. E., Duennwald M., Markovic P., et al,. (2006) Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 15, 2743-2751.
72. Ehrnhoefer D. E., Butland S. L., Pouladi M. A., and, Hayden M. R., (2009) Mouse models of Huntington disease: variations on a theme. Dis. Model. Mech. 2, 123-129.
73. Falk J. D., Vargiu P., Foye P. E., Usui H., Perez J., Danielson P. E., Lerner D. L., Bernal J., and, Sutcliffe J. G., (1999) Rhes: a striatal-specific Ras homolog related to Dexras1. J. Neurosci. Res. 57, 782-788.
74. Feigin A., Ghilardi M. F., Huang C., Ma Y., Carbon M., Guttman M., Paulsen J. S., Ghez C. P., and, Eidelberg D., (2006) Preclinical Huntington's disease: compensatory brain responses during learning. Ann. Neurol. 59, 53-59.
75. Ferrante R. J., Kowall N. W., Cipolloni P. B., Storey E., and, Beal M. F., (1993) Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol. 119, 46-71.
76. Ferrante R. J., Gutekunst C. A., Persichetti F., McNeil S. M., Kowall N. W., Gusella J. F., MacDonald M. E., Beal M. F., and, Hersch S. M., (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17, 3052-3063.
77. Figueredo-Cardenas G., Harris C. L., Anderson K. D., and, Reiner A., (1998) Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp. Neurol. 149, 356-372.
78. Firdaus W. J. J., Wyttenbach A., Giuliano P., Kretz-Remy C., Currie R. W., and, Arrigo A.-P., (2006) Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J. 273, 5428-5441.
79. Fisher E. R., and, Hayden M. R., (2013) Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov. Disord. n/a-n/a.
80. Fox J. H., Kama J. A., Lieberman G., Chopra R., Dorsey K., Chopra V., Volitakis I., Cherny R. A., Bush A. I., and, Hersch S., (2007) Mechanisms of copper ion mediated Huntington's disease progression. PLoS ONE 2, e334.
81. Friedman A., Arosio P., Finazzi D., Koziorowski D., and, Galazka-Friedman J., (2011) Ferritin as an important player in neurodegeneration. Parkinsonism Relat. Disord. 17, 423-430.
82. Gafni J., Hermel E., Young J. E., Wellington C. L., Hayden M. R., and, Ellerby L. M., (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279, 20211-20220.
83. Ganz T., and, Nemeth E., (2011) Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 62, 347-360.
84. Gauthier L. R., Charrin B. C., Borrell-Pagès M., et al,. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138.
85. Gelman N., Gorell J. M., Barker P. B., Savage R. M., Spickler E. M., Windham J. P., and, Knight R. A., (1999) MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 210, 759-767.
86. Gerlach M., Double K., Riederer P., Hirsch E., Jellinger K., Jenner P., Trautwein A., and, Youdim M. B., (1997) Iron in the Parkinsonian substantia nigra. Mov. Disord. 12, 258-260.
87. Gerlach M., Double K. L., Ben-Shachar D., Zecca L., Youdim M. B. H., and, Riederer P., (2003) Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox. Res. 5, 35-44.
88. Giorgini F., and, Muchowski P. J., (2005) Connecting the dots in Huntington's disease with protein interaction networks. Genome Biol. 6, 210.
89. Gkouvatsos K., Papanikolaou G., and, Pantopoulos K., (2012) Regulation of iron transport and the role of transferrin. Biochim. Biophys. Acta 1820, 188-202.
90. Goehler H., Lalowski M., Stelzl U., et al,. (2004) A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell 15, 853-865.
91. Gõmez-Tortosa E., MacDonald M. E., Friend J. C., et al,. (2001) Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 49, 29-34.
92. Gonitel R., Moffitt H., Sathasivam K., Woodman B., Detloff P. J., Faull R. L. M., and, Bates G. P., (2008) DNA instability in postmitotic neurons. Proc. Natl Acad. Sci. USA 105, 3467-3472.
93. González-Cortés C., Salinas-Lara C., Gõmez- Lõpez M. A., et al,. (2008) Iron porphyrinate Fe(TPPS) reduces brain cell damage in rats intrastriatally lesioned by quinolinate. Neurotoxicol. Teratol. 30, 510-519.
94. Goula A.-V., Berquist B. R., Wilson D. M., Wheeler V. C., Trottier Y., and, Merienne K., (2009) Stoichiometry of base excision repair proteins correlates with increased somatic CAG instability in striatum over cerebellum in Huntington's disease transgenic mice. PLoS Genet. 5, e1000749.
95. Gregory A., and, Hayflick S. J., (2011) Genetics of neurodegeneration with brain iron accumulation. Curr. Neurol. Neurosci. Rep. 11, 254-261.
96. Grimaud J., Millar J., Thorpe J. W., Moseley I. F., McDonald W. I., and, Miller D. H., (1995) Signal intensity on MRI of basal ganglia in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 59, 306-308.
97. Gu M., Gash M. T., Mann V. M., Javoy-Agid F., Cooper J. M., and, Schapira A. H., (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385-389.
98. Guo J., Zhu P., Wu C., Yu L., Zhao S., and, Gu X., (2003) In silico analysis indicates a similar gene expression pattern between human brain and testis. Cytogenet. Genome Res. 103, 58-62.
99. Gusella J. F., and, MacDonald M. E., (2009) Huntington's disease: the case for genetic modifiers. Genome Med. 1, 80.
100. Hadziahmetovic M., Song Y., Wolkow N., et al,. (2011) The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Invest. Ophthalmol. Vis. Sci. 52, 959-968.
101. Halliwell B., (1992) Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
102. Hands S., Sajjad M. U., Newton M. J., and, Wyttenbach A., (2011) In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J. Biol. Chem. 286, 44512-44520.
103. Hare D., Ayton S., Bush A., and, Lei P., (2013) A delicate balance: iron metabolism and diseases of the brain. Front. Aging Neurosci. 5, 34.
104. Harjes P., and, Wanker E. E., (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28, 425-433.
105. Harms L., Meierkord H., Timm G., Pfeiffer L., and, Ludolph A. C., (1997) Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J. Neurol. Neurosurg. Psychiatry 62, 27-30.
106. Harrison P. M., and, Arosio P., (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275, 161-203.
107. Harrison L. M., Muller S. H., and, Spano D., (2013) Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum. Neuroscience 236, 21-30.
108. Hayflick S. J., Penzien J. M., Michl W., Sharif U. M., Rosman N. P., and, Wheeler P. G., (2001) Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr. Neurol. 25, 166-169.
109. Henley S. M. D., Wild E. J., Hobbs N. Z., Frost C., MacManus D. G., Barker R. A., Fox N. C., and, Tabrizi S. J., (2009) Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov. Disord. 24, 932-936.
110. Hermel E., Gafni J., Propp S. S., et al,. (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 11, 424-438.
111. Heron P., Cousins K., Boyd C., and, Daya S., (2001) Paradoxical effects of copper and manganese on brain mitochondrial function. Life Sci. 68, 1575-1583.
112. Heyser C. J., Fienberg A. A., Greengard P., and, Gold L. H., (2000) DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task. Brain Res. 867, 122-130.
113. Hilditch-Maguire P., Trettel F., Passani L. A., Auerbach A., Persichetti F., and, MacDonald M. E., (2000) Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 9, 2789-2797.
114. Hiroi N., Fienberg A. A., Haile C. N., Alburges M., Hanson G. R., Greengard P., and, Nestler E. J., (1999) Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur. J. Neurosci. 11, 1114-1118.
115. Ho L. W., Brown R., Maxwell M., Wyttenbach A., and, Rubinsztein D. C., (2001) Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. J. Med. Genet. 38, 450-452.
116. Hogarth P., Gregory A., Kruer M. C., et al,. (2013) New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 80, 268-275.
117. Huang X., Atwood C. S., Hartshorn M. A., et al,. (1999a) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609-7616.
118. Huang X., Cuajungco M. P., Atwood C. S., et al,. (1999b) Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274, 37111-37116.
119. Jellinger K. A., (1999) The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14, 115-140.
120. Jensen J. H., Chandra R., Ramani A., Lu H., Johnson G., Lee S.-P., Kaczynski K., and, Helpern J. A., (2006) Magnetic field correlation imaging. Magn. Reson. Med. 55, 1350-1361.
121. Jeong S. Y., and, David S., (2003) Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278, 27144-27148.
122. Jurgens C. K., van de Wiel L., van Es A. C., Grimbergen Y. M., Witjes-Ane M. N., van der Grond J., Middelkoop H. A., and, Roos R. A., (2008) Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. J. Neurol. 255, 1785-1791.
123. Jurgens C. K., Jasinschi R., Ekin A., Witjes-Ané M.-N. W., Middelkoop H., van der Grond J., and, Roos R. A. C., (2010) MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Curr. 2, RRN1173.
124. Kalchman M. A., Graham R. K., Xia G., Koide H. B., Hodgson J. G., Graham K. C., Goldberg Y. P., Gietz R. D., Pickart C. M., and, Hayden M. R., (1996) Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271, 19385-19394.
125. Kasischke K. A., Vishwasrao H. D., Fisher P. J., Zipfel W. R., and, Webb W. W., (2004) Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 305, 99-103.
126. Kaur D., Yantiri F., Rajagopalan S., et al,. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909.
127. Kim Y. J., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K. B., Qin Z. H., Aronin N., and, DiFiglia M., (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl Acad. Sci. USA 98, 12784-12789.
128. Kim M. W., Chelliah Y., Kim S. W., Otwinowski Z., and, Bezprozvanny I., (2009) Secondary structure of Huntingtin amino-terminal region. Structure 17, 1205-1212.
129. Kitzberger R., Madl C., and, Ferenci P., (2005) Wilson disease. Metab. Brain Dis. 20, 295-302.
130. Koeppen A. H., (1995) The history of iron in the brain. J. Neurol. Sci. 134 (Suppl), 1-9.
131. Kono S., (2012) Aceruloplasminemia. Curr. Drug Targets 13, 1190-1199.
132. Krause A., Neitz S., Mägert H. J., Schulz A., Forssmann W. G., Schulz-Knappe P., and, Adermann K., (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480, 147-150.
133. Kruer M. C., Boddaert N., Schneider S. A., Houlden H., Bhatia K. P., Gregory A., Anderson J. C., Rooney W. D., Hogarth P., and, Hayflick S. J., (2012) Neuroimaging features of neurodegeneration with brain iron accumulation. Am. J. Neuroradiol. 33, 407-414.
134. Kurz T., Gustafsson B., and, Brunk U. T., (2006) Intralysosomal iron chelation protects against oxidative stress-induced cellular damage. FEBS J. 273, 3106-3117.
135. Lambe T., Simpson R. J., Dawson S., et al,. (2009) Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. Blood 113, 1805-1808.
136. Langkammer C., Krebs N., Goessler W., Scheurer E., Ebner F., Yen K., Fazekas F., and, Ropele S., (2010) Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 257, 455-462.
137. Leavitt B. R., Guttman J. A., Hodgson J. G., Kimel G. H., Singaraja R., Vogl A. W., and, Hayden M. R., (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 68, 313-324.
138. Leavitt B. R., Van Raamsdonk J. M., Shehadeh J., Fernandes H., Murphy Z., Graham R. K., Wellington C. L., Raymond L. A., and, Hayden M. R., (2006) Wild-type huntingtin protects neurons from excitotoxicity. J. Neurochem. 96, 1121-1129.
139. Lee H. K., Barbarosie M., Kameyama K., Bear M. F., and, Huganir R. L., (2000) Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405, 955-959.
140. Lee A., Anderson A. R., Barnett A. C., Chan A., and, Pow D. V., (2011) Expression of multiple glutamate transporter splice variants in the rodent testis. Asian J. Androl. 13, 254-265.
141. Lei P., Ayton S., Finkelstein D. I., et al,. (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291-295.
142. Leveugle B., Mazurier J., Legrand D., Mazurier C., Montreuil J., and, Spik G., (1993) Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. Eur. J. Biochem. 213, 1205-1211.
143. Levi S., Santambrogio P., Albertini A., and, Arosio P., (1993) Human ferritin H-chains can be obtained in non-assembled stable forms which have ferroxidase activity. FEBS Lett. 336, 309-312.
144. Levi S., Corsi B., Bosisio M., Invernizzi R., Volz A., Sanford D., Arosio P., and, Drysdale J., (2001) A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. 276, 24437-24440.
145. Li X. J., and, Li S., (2011) Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 43, 4-8.
146. Li J.-Y., Plomann M., and, Brundin P., (2003) Huntington's disease: a synaptopathy? Trends Mol. Med. 9, 414-420.
147. Lodi R., Schapira A. H., Manners D., Styles P., Wood N. W., Taylor D. J., and, Warner T. T., (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48, 72-76.
148. Lumsden A. L., Henshall T. L., Dayan S., Lardelli M. T., and, Richards R. I., (2007) Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum. Mol. Genet. 16, 1905-1920.
149. Lunkes A., Lindenberg K. S., Ben-Haïem L., Weber C., Devys D., Landwehrmeyer G. B., Mandel J.-L., and, Trottier Y., (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 10, 259-269.
150. Luo S., Vacher C., Davies J. E., and, Rubinsztein D. C., (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J. Cell Biol. 169, 647-656.
151. MacDonald M. E., and, Gusella J. F., (1996) Huntington's disease: translating a CAG repeat into a pathogenic mechanism. Curr. Opin. Neurobiol. 6, 638-643.
152. Martin J. B., and, Gusella J. F., (1986) Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 315, 1267-1276.
153. Martinez-Vicente M., Talloczy Z., Wong E., et al,. (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat. Neurosci. 13, 567-576.
154. McGahan M. C., Harned J., Mukunnemkeril M., Goralska M., Fleisher L., and, Ferrell J. B., (2005) Iron alters glutamate secretion by regulating cytosolic aconitase activity. Am. J. Physiol. Cell Physiol. 288, C1117-C1124.
155. Mealer R. G., Subramaniam S., and, Snyder S. H., (2013) Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease. J. Neurosci. 33, 4206-4210.
156. Mealer R. G., Murray A. J., Shahani N., Subramaniam S., and, Snyder S. H., (2014) Rhes, a Striatal-selective Protein Implicated in Huntington Disease, Binds Beclin-1 and Activates Autophagy. J. Biol. Chem. 289, 3547-3554.
157. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., and, Chesselet M. F., (2000) Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 162, 328-342.
158. Metzler M., Chen N., Helgason C. D., Graham R. K., Nichol K., McCutcheon K., Nasir J., Humphries R. K., Raymond L. A., and, Hayden M. R., (1999) Life without huntingtin: normal differentiation into functional neurons. J. Neurochem. 72, 1009-1018.
159. Metzler M., Helgason C. D., Dragatsis I., Zhang T., Gan L., Pineault N., Zeitlin S. O., Humphries R. K., and, Hayden M. R., (2000) Huntingtin is required for normal hematopoiesis. Hum. Mol. Genet. 9, 387-394.
160. Metzler M., Legendre-Guillemin V., Gan L., Chopra V., Kwok A., McPherson P. S., and, Hayden M. R., (2001) HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J. Biol. Chem. 276, 39271-39276.
161. Metzler M., Gan L., Wong T. P., et al,. (2007) NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1. J. Neurosci. 27, 2298-2308.
162. Michaeli S., Oz G., Sorce D. J., Garwood M., Ugurbil K., Majestic S., and, Tuite P., (2007) Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov. Disord. 22, 334-340.
163. Mitra S., Tsvetkov A. S., and, Finkbeiner S., (2009) Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease. J. Biol. Chem. 284, 4398-4403.
164. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., and, Gitlin J. D., (1997) Use of desferrioxamine in the treatment of aceruloplasminemia. Ann. Neurol. 41, 404-407.
165. Montine T. J., Beal M. F., Robertson D., Cudkowicz M. E., Biaggioni I., O'Donnell H., Zackert W. E., Roberts L. J., and, Morrow J. D., (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 52, 1104-1105.
166. Morrison P. J., and, Nevin N. C., (1994) Serum iron, total iron binding capacity and ferritin in early Huntington disease patients. Ir. J. Med. Sci. 163, 236-237.
167. Moumné L., Betuing S., and, Caboche J., (2013) Multiple aspects of gene dysregulation in Huntington's Disease. Front. Neurol. 4, 127.
168. Myers R. H., Vonsattel J. P., Paskevich P. A., Kiely D. K., Stevens T.
169. Nagata E., Sawa A., Ross C. A., and, Snyder S. H., (2004) Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. NeuroReport 15, 1325-1328.
170. Nasir J., Floresco S. B., O'Kusky J. R., Diewert V. M., Richman J. M., Zeisler J., Borowski A., Marth J. D., Phillips A. G., and, Hayden M. R., (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811-823.
171. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B. K., and, Ganz T., (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113, 1271-1276.
172. Nguyen T., Hamby A., and, Massa S. M., (2005) Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington' disease mouse model. Proc. Natl Acad. Sci. USA 102, 11840-11845.
173. Nishii T., Hirata A., Masaki T., Kaida K., Nakamura R., Motoyoshi K., and, Kamakura K., (2000) Reduced signal intensity of T2 weighted MR imaging of thalamus and putamen in multiple sclerosis in Japan. Rinsho Shinkeigaku 40, 677-682.
174. Nopoulos P. C., Aylward E. H., Ross C. A., et al,. and Coordinators of the Huntington Study G. (2011) Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain 134, 137-142.
175. Novak M. J. U., and, Tabrizi S. J., (2010) Huntington's disease. BMJ 340, c3109.
176. Okamoto S., Pouladi M. A., Talantova M., et al,. (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15, 1407-1413.
177. O'Kusky J. R., Nasir J., Cicchetti F., Parent A., and, Hayden M. R., (1999) Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Res. 818, 468-479.
178. Pandolfo M., and, Hausmann L., (2013) Deferiprone for the treatment of Friedreich's ataxia. J. Neurochem. 126 (Suppl 1), 142-146.
179. Pantopoulos K., (2004) Iron metabolism and the IRE/IRP regulatory system: an update. Ann. N. Y. Acad. Sci. 1012, 1-13.
180. Pantopoulos K., Porwal S. K., Tartakoff A., and, Devireddy L., (2012) Mechanisms of mammalian iron homeostasis. Biochemistry 51, 5705-5724.
181. Park C. H., Valore E. V., Waring A. J., and, Ganz T., (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276, 7806-7810.
182. Paulsen J. S., Nopoulos P. C., Aylward E., Ross C. A., Johnson H., Magnotta V. A., Juhl A., Pierson R. K., Mills J., Langbehn D., and, Nance M., (2010) PREDICT-HD investigators and coordinators of the Huntington's study group: striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res. Bull. 82, 201-207.
183. Pavese N., Gerhard A., Tai Y. F., Ho A. K., Turkheimer F., Barker R. A., Brooks D. J., and, Piccini P., (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66, 1638-1643.
184. Pérez-De La Cruz V., González-Cortés C., Galván-Arzate S., Medina-Campos O. N., Pérez-Severiano F., Ali S. F., Pedraza-Chaverrí J., and, Santamaría A., (2005) Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III). Neuroscience 135, 463-474.
185. Pérez-De La Cruz V., Elinos-Calderõn D., Robledo-Arratia Y., Medina-Campos O. N., Pedraza-Chaverrí J., Ali S. F., and, Santamaría A., (2009) Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease. Behav. Brain Res. 199, 210-217.
186. Pfefferbaum A., Adalsteinsson E., Rohlfing T., and, Sullivan E. V., (2009) MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. NeuroImage 47, 493-500.
187. Philpott C. C., (2012) Coming into view: eukaryotic iron chaperones and intracellular iron delivery. J. Biol. Chem. 287, 13518-13523.
188. Pujol J., Junqué C., Vendrell P., Grau J. M., Martí-Vilalta J. L., Olivé C., and, Gili J., (1992) Biological significance of iron-related magnetic resonance imaging changes in the brain. Arch. Neurol. 49, 711-717.
189. Qin L., Liu Y., Hong J.-S., and, Crews F. T., (2013) NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 61, 855-868.
190. Quintero G. C., Spano D., Lahoste G. J., and, Harrison L. M., (2008) The Ras homolog Rhes affects dopamine D1 and D2 receptor-mediated behavior in mice. NeuroReport 19, 1563-1566.
191. Ranen N. G., Stine O. C., Abbott M. H., Sherr M., Codori A. M., Franz M. L., Chao N. I., Chung A. S., Pleasant N., and, Callahan C., (1995) Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am. J. Hum. Genet. 57, 593-602.
192. Rangone H., Poizat G., Troncoso J., Ross C. A., MacDonald M. E., Saudou F., and, Humbert S., (2004) The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci. 19, 273-279.
193. Rasia R. M., Bertoncini C. W., Marsh D., Hoyer W., Cherny D., Zweckstetter M., Griesinger C., Jovin T. M., and, Fernández C. O., (2005) Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc. Natl Acad. Sci. USA 102, 4294-4299.
194. Rathore K. I., Redensek A., and, David S., (2012) Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-α and TGF-β1. Glia 60, 738-750.
195. Ravikumar B., Vacher C., Berger Z., Davies J. E., Luo S., Oroz L. G., Scaravilli F., Easton D. F., Duden R., and, Os;Kane C. J. and Rubinsztein D. C., (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585-595.
196. Reddy P. H., and, Shirendeb U. P., (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim. Biophys. Acta 1822, 101-110.
197. Richardson D. R., Lane D. J. R., Becker E. M., Huang M. L.-H., Whitnall M., Suryo Rahmanto Y., Sheftel A. D., and, Ponka P., (2010) Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc. Natl Acad. Sci. USA 107, 10775-10782.
198. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K., and, Youdim M. B., (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
199. Rigamonti D., Bauer J. H., De-Fraja C., et al,. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20, 3705-3713.
200. Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E., and, Cattaneo E., (2001) Huntingtins neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 276, 14545-14548.
201. Rosas H. D., Goodman J., Chen Y. I., Jenkins B. G., Kennedy D. N., Makris N., Patti M., Seidman L. J., Beal M. F., and, Koroshetz W. J., (2001) Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 57, 1025-1028.
202. Rosas H. D., Koroshetz W. J., Chen Y. I., et al,. (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60, 1615-1620.
203. Rosas H. D., Tuch D. S., Hevelone N. D., Zaleta A. K., Vangel M., Hersch S. M., and, Salat D. H., (2006) Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 21, 1317-1325.
204. Rosas H. D., Chen Y. I., Doros G., Salat D. H., Chen N.-K., Kwong K. K., Bush A., Fox J., and, Hersch S. M., (2012) Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch. Neurol. 69, 887-893.
205. Ross S. L., Tran L., Winters A., et al,. (2012) Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 15, 905-917.
206. Rouault T. A., (2001) Systemic iron metabolism: a review and implications for brain iron metabolism. Pediatr. Neurol. 25, 130-137.
207. Rouault T. A., (2013) Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 14, 551-564.
208. Roze E., Saudou F., and, Caboche J., (2008) Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr. Opin. Neurol. 21, 497-503.
209. Rubinsztein D. C., Barton D. E., Davison B. C., and, Ferguson-Smith M. A., (1993) Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. Hum. Mol. Genet. 2, 1713-1715.
210. Russo N., Edwards M., Andrews T., O'Brien M., and, Bhatia K. P., (2004) Hereditary haemochromatosis is unlikely to cause movement disorders-a critical review. J. Neurol. 251, 849-852.
211. Sanchez-Castaneda C., Cherubini A., Elifani F., Peran P., Orobello S., Capelli G., Sabatini U., and, Squitieri F., (2013) Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum. Brain Mapp. 34, 1625-1635.
212. Santambrogio P., Biasiotto G., Sanvito F., Olivieri S., Arosio P., and, Levi S., (2007) Mitochondrial ferritin expression in adult mouse tissues. J. Histochem. Cytochem. 55, 1129-1137.
213. Sassone J., Colciago C., Cislaghi G., Silani V., and, Ciammola A., (2009) Huntington's disease: the current state of research with peripheral tissues. Exp. Neurol. 219, 385-397.
214. Sbodio J. I., Paul B. D., Machamer C. E., and, Snyder S. H., (2013) Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease. Cell Rep. 4, 890-897.
215. Schapira A., and, Lodi R., (2004) Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. Methods Mol. Biol. 277, 293-307.
216. Schenck J. F., (2003) Magnetic resonance imaging of brain iron. J. Neurol. Sci. 207, 99-102.
217. Schilling B., Gafni J., Torcassi C., et al,. (2006) Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J. Biol. Chem. 281, 23686-23697.
218. Schrag M., Dickson A., Jiffry A., Kirsch D., Vinters H. V., and, Kirsch W., (2010) The effect of formalin fixation on the levels of brain transition metals in archived samples. Biometals 23, 1123-1127.
219. Schulz K., Vulpe C. D., Harris L. Z., and, David S., (2011) Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J. Neurosci. 31, 13301-13311.
220. Schwarcz R., Bennett J. P., and, Coyle J. T., (1977) Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease. J. Neurochem. 28, 867-869.
221. Semaka A., Kay C., Doty C., Collins J. A., Bijlsma E. K., Richards F., Goldberg Y. P., and, Hayden M. R., (2013) CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. J. Med. Genet. 50, 696-703.
222. Seredenina T., Gokce O., and, Luthi-Carter R., (2011) Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation. PLoS ONE 6, e22231.
223. Sheline C. T., and, Choi D. W., (2004) Cu2 + toxicity inhibition of mitochondrial dehydrogenases in vitro and in vivo. Ann. Neurol. 55, 645-653.
224. Shi H., Bencze K. Z., Stemmler T. L., and, Philpott C. C., (2008) A cytosolic iron chaperone that delivers iron to ferritin. Science 320, 1207-1210.
225. Shimojo M., (2008) Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued. J. Biol. Chem. 283, 34880-34886.
226. Shoham S., and, Youdim M. B., (2000) Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell. Mol. Biol. 46, 743-760.
227. Simmons D. A., Casale M., Alcon B., Pham N., Narayan N., and, Lynch G., (2007) Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55, 1074-1084.
228. Smith M. A., Sayre L. M., Monnier V. M., and, Perry G., (1996) Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol. Chem. Neuropathol. 28, 41-48.
229. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G., and, Youdim M. B., (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199-205.
230. Song C., Zhang Y., Parsons C. G., and, Liu Y. F., (2003) Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J. Biol. Chem. 278, 33364-33369.
231. Sorolla M. A., Reverter-Branchat G., Tamarit J., Ferrer I., Ros J., and, Cabiscol E., (2008) Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radical Biol. Med. 45, 667-678.
232. Sorolla M. A., Rodríguez-Colman M. J., Tamarit J., Ortega Z., Lucas J. J., Ferrer I., Ros J., and, Cabiscol E., (2010) Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radical Biol. Med. 49, 612-621.
233. Sorolla M. A., Rodríguez-Colman M. J., Vall-llaura N., Tamarit J., Ros J., and, Cabiscol E., (2012) Protein oxidation in Huntington disease. BioFactors 38, 173-185.
234. Stachowski E. K., and, Schwarcz R., (2012) Regulation of quinolinic acid neosynthesis in mouse, rat and human brain by iron and iron chelators in vitro. J. Neural Transm. 119, 123-131.
235. Stankiewicz J., Panter S. S., Neema M., Arora A., Batt C. E., and, Bakshi R., (2007) Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 4, 371-386.
236. Steffan J. S., Agrawal N., Pallos J., et al,. (2004) SUMO modification of Huntingtin and Huntington's disease pathology. Science 304, 100-104.
237. Subramaniam S., Sixt K. M., Barrow R., and, Snyder S. H., (2009) Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324, 1327-1330.
238. Sun Y., Savanenin A., Reddy P. H., and, Liu Y. F., (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713-24718.
239. Surmeier D. J., Song W. J., and, Yan Z., (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16, 6579-6591.
240. Tabrizi S. J., Langbehn D. R., Leavitt B. R., et al,. (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 8, 791-801.
241. Tabrizi S. J., Scahill R. I., Durr A., et al,. (2011) Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 10, 31-42.
242. Tang T.-S., Tu H., Chan E. Y. W., Maximov A., Wang Z., Wellington C. L., Hayden M. R., and, Bezprozvanny I., (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39, 227-239.
243. Tang T.-S., Slow E., Lupu V., Stavrovskaya I. G., Sugimori M., Llinás R., Kristal B. S., Hayden M. R., and, Bezprozvanny I., (2005) Disturbed Ca2 + signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl Acad. Sci. USA 102, 2602-2607.
244. Tartari M., Gissi C., Lo Sardo V., Zuccato C., Picardi E., Pesole G., and, Cattaneo E., (2008) Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol. Biol. Evol. 25, 330-338.
245. Thompson L. M., Aiken C. T., Kaltenbach L. S., et al,. (2009) IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187, 1083-1099.
246. Thu D. C. V., Oorschot D. E., Tippett L. J., Nana A. L., Hogg V. M., Synek B. J., Luthi-Carter R., Waldvogel H. J., and, Faull R. L. M., (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 133, 1094-1110.
247. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V. C., Sharp A. H., Persichetti F., Cattaneo E., and, MacDonald M. E., (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799-2809.
248. Túnez I., Sánchez-Lõpez F., Agüera E., Fernández-Bolaños R., Sánchez F. M., and, Tasset-Cuevas I., (2011) Important role of oxidative stress biomarkers in Huntington's disease. J. Med. Chem. 54, 5602-5606.
249. Valdes Hernandez M. C., Jeong T. H., Murray C., Bastin M. E., Chappell F. M., Deary I. J., and, Wardlaw J. M., (2011) Reliability of two techniques for assessing cerebral iron deposits with structural magnetic resonance imaging. J. Magn. Reson. Imaging 33, 54-61.
250. Valentine J. S., and, Hart P. J., (2003) Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 100, 3617-3622.
251. Van Raamsdonk J. M., Pearson J., Rogers D. A., Bissada N., Vogl A. W., Hayden M. R., and, Leavitt B. R., (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14, 1379-1392.
252. Van Raamsdonk J. M., Gibson W. T., Pearson J., Murphy Z., Lu G., Leavitt B. R., and, Hayden M. R., (2006) Body weight is modulated by levels of full-length huntingtin. Hum. Mol. Genet. 15, 1513-1523.
253. Van Raamsdonk J. M., Murphy Z., Selva D. M., et al,. (2007) Testicular degeneration in Huntington disease. Neurobiol. Dis. 26, 512-520.
254. Vargiu P., De Abajo R., Garcia-Ranea J. A., Valencia A., Santisteban P., Crespo P., and, Bernal J., (2004) The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors. Oncogene 23, 559-568.
255. Velier J., Kim M., Schwarz C., Kim T. W., Sapp E., Chase K., Aronin N., and, DiFiglia M., (1998) Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152, 34-40.
256. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D., and, Richardson E. P., (1985) Neuropathological classification of Huntington& apos;s disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
257. Vymazal J., Hajek M., Patronas N., Giedd J. N., Bulte J. W., Baumgarner C., Tran V., and, Brooks R. A., (1995) The quantitative relation between T1-weighted and T2-weighted MRI of normal gray matter and iron concentration. J. Magn. Reson. Imaging 5, 554-560.
258. Vymazal J., Klempír J., Jech R., Zidovská J., Syka M., Růzicka E., and, Roth J., (2007) MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters. J. Neurol. Sci. 263, 20-25.
259. Walker F. O., (2010) Does hereditary hemochromatosis influence the age of onset of Huntington's disease? Mov. Disord. 25, 946.
260. Wang J., and, Pantopoulos K., (2011) Regulation of cellular iron metabolism. Biochem. J. 434, 365-381.
261. Warby S. C., Chan E. Y., Metzler M., Gan L., Singaraja R. R., Crocker S. F., Robertson H. A., and, Hayden M. R., (2005) Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum. Mol. Genet. 14, 1569-1577.
262. Weiss G., (2009) Iron metabolism in the anemia of chronic disease. Biochim. Biophys. Acta 1790, 682-693.
263. Wellington C. L., Ellerby L. M., Gutekunst C.-A., et al,. (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22, 7862-7872.
264. Weydt P., Pineda V. V., Torrence A. E., et al,. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4, 349-362.
265. Williams B. B., Kwakye G. F., Wegrzynowicz M., Li D., Aschner M., Erikson K. M., and, Bowman A. B., (2010a) Altered manganese homeostasis and manganese toxicity in a Huntingtons disease striatal cell model are not explained by defects in the iron transport system. Toxicol. Sci. 117, 169-179.
266. Williams B. B., Li D., Wegrzynowicz M., Vadodaria B. K., Anderson J. G., Kwakye G. F., Aschner M., Erikson K. M., and, Bowman A. B., (2010b) Disease-toxicant screen reveals a neuroprotective interaction between Huntingtons disease and manganese exposure. J. Neurochem. 112, 227-237.
267. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A.-P., and, Rubinsztein D. C., (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11, 1137-1151.
268. Xia J., Lee D. H., Taylor J., Vandelft M., and, Truant R., (2003) Huntingtin contains a highly conserved nuclear export signal. Hum. Mol. Genet. 12, 1393-1403.
269. Yanai A., Huang K., Kang R., et al,. (2006) Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat. Neurosci. 9, 824-831.
270. Youdim M. B., Ben-Shachar D., and, Riederer P., (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8, 1-12.
271. Youdim M. B. H., Stephenson G., and, Ben-Shachar D., (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 1012, 306-325.
272. Zala D., Hinckelmann M.-V., Yu H., Lyra da Cunha M. M., Liot G., Cordelières F. P., Marco S., and, Saudou F., (2013) Vesicular glycolysis provides on-board energy for fast axonal transport. Cell 152, 479-491.
273. Zecca L., Youdim M. B. H., Riederer P., Connor J. R., and, Crichton R. R., (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873.
274. Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P., Hayden M. R., and, Raymond L. A., (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860.
275. Zhang Y., Li M., Drozda M., et al,. (2003) Depletion of wild-type huntingtin in mouse models of neurologic diseases. J. Neurochem. 87, 101-106.
276. Zhang Y., Leavitt B. R., Van Raamsdonk J. M., Dragatsis I., Goldowitz D., MacDonald M. E., Hayden M. R., and, Friedlander R. M., (2006) Huntingtin inhibits caspase-3 activation. EMBO J. 25, 5896-5906.
277. Zhao G., Arosio P., and, Chasteen N. D., (2006) Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin. An EPR spin-trapping study. Biochemistry 45, 3429-3436.
278. Zheng S., Clabough E. B., Sarkar S., Futter M., Rubinsztein D. C., and, Zeitlin S. O., (2010) Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet. 6, e1000838.
279. Zuccato C., and, Cattaneo E., (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81, 294-330.
280. Zuccato C., Valenza M., and, Cattaneo E., (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 90, 905-981.